UNSPSC 51402203: Buspirone

This classification denotes an anxiolytic with the molecular formula C21H31N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TK65WKS8HL, chemically known as 8-azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)- but generally known as buspirone, which bears US NIH Compound Identifier 2477. Buspirone most often comes in base and hydrochloride forms. European Medicines Agency schedules Buspirone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05992MIG.

UNSPSC 51402203 Buspirone is a Commodity code that nominally classifies individual pharmaceutical active ingredients, but recent state and local procurement activity under this code does not focus on buspirone itself. Instead, issuing bodies are procuring broader pharmaceutical and health-supply categories including naloxone, over-the-counter products, and generic multi-source medications through competitive bidding and cooperative purchasing vehicles. State and local buyers under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves establishing supply contracts for pharmaceutical products with detailed compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, E-Verify and drug-free workplace verification, and specific insurance coverages (commercial general liability, workers' compensation, professional liability). Vendors must demonstrate capacity to deliver products through authorized wholesaler networks, meet FDA requirements, maintain minimum shelf-life standards, and accept fixed-fee or net-pricing models with administrative fees.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, and potentially funded through FEMA. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring manufacturer compliance with cGMP, DSCSA, and submission through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.